FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms
Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in...
Saved in:
Main Authors: | Manish Kumar, Abhishek Singh Sengar, Anushree Lye, Pranesh Kumar, Sukhes Mukherjee, Dinesh Kumar, Priyadip Das, Suvro Chatterjee, Adele Stewart, Biswanath Maity |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Redox Biology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725000400 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01) -
Cardiotoxicity of polystyrene nanoplastics and associated mechanism of myocardial cell injury in mice
by: Ziyi Xiong, et al.
Published: (2025-01-01) -
Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling
by: Conagh Kelly, et al.
Published: (2025-02-01) -
Research Progress of ROS-Mitochondrial Pathway on Cardiovascular Protection of Tea Polyphenols
by: Tingting DENG, et al.
Published: (2025-02-01) -
Association of Serum Irisin With Severity and Prognosis in Patients With Coronavirus Disease 2019: A Prospective Cohort Study
by: Zhang X, et al.
Published: (2025-02-01)